Dirk Schadendorf
YOU?
Author Swipe
View article: Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
RNASeq data for the MDA cohort (n=61) with associated clinical info.
View article: Supplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Supplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance Open
Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61
View article: Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
Immune cell analysis by BMI. A. Immunohistochemistry (IHC) analysis for CD8-, CD45RO-, FOXP3-, CD68-, GZMB-, PD-1-, LAG-3-, and CD3-positive cells in overweight/obese (OW/OB) verse normal (NL) tumors as defined by body mass index from the …
View article: Supplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Supplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance Open
HLA-II expression in longitudinal melanoma samples
View article: Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
Integrated gene set enrichment analysis of subgroups by body mass index BMI. This figure compares gene expression between overweight/obese (OW/OB) and normal (NL) BMI patients with metastatic melanoma across subgroups by sex, cohort, and t…
View article: Supplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Supplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance Open
No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells
View article: Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 …
View article: Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
Differential gene expression analysis for covariates controlled.
View article: Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort…
View article: Supplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Supplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance Open
ConstHLA-II melanoma cells lack endogenous interferon expression
View article: Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma Open
Reverse phase protein array of the PI3K pathway expression by BMI. Box plot represents the median bar with the box bounding IQR and whiskers the minimum and maximum values.
View article: Supplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Supplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance Open
JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells
View article: Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization
Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization Open
Supplementary Movie 1
View article: Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization
Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization Open
Supplementary Movie 3
View article: Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization
Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization Open
Supplementary Movie 4
View article: Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization
Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization Open
Supplementary Movie 5
View article: Messages for ultraviolet‐radiation protection to fair‐skinned populations
Messages for ultraviolet‐radiation protection to fair‐skinned populations Open
Background Skin cancer prevention remains a critical public health challenge, particularly in fair‐skinned populations in Europe, the United States and Australia, where incidence rates of keratinocyte skin cancer and melanoma continue to r…
View article: 600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma
600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma Open
View article: 611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy: a subgroup analysis of patients with anti-PD-1-failed <i>BRAF</i> -mutant melanoma from the IGNYTE clinical trial
611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy: a subgroup analysis of patients with anti-PD-1-failed <i>BRAF</i> -mutant melanoma from the IGNYTE clinical trial Open
View article: 1327 Biomarker and updated clinical data for RP1 plus nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade
1327 Biomarker and updated clinical data for RP1 plus nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade Open
View article: Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance Open
View article: Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss
Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss Open
View article: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial Open
Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma. Here, to address a current unmet need for more efficacious adjuvant regimens for completely resected melanoma, the phase 3, double-blind RELATIVITY-098 t…
View article: Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification Open
This study evaluates the CT-based volumetric sarcopenia index (SI) as a baseline prognostic factor for overall survival (OS) in 10,340 solid tumor patients (40% female). Automated body composition analysis was applied to internal baseline …
View article: Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study Open
View article: Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response
Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response Open
Melanoma patients with in-transit metastasis (ITM), a stage of disease where melanoma has metastasized to sites in between the primary lesion and draining lymph node, vary significantly in their clinical outcomes, but the biology driving d…
View article: Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
CD8 characterization in the TME.
View article: Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Changes in immune cell populations in the NIVO + RELA arm from baseline to week 4.
View article: Data from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Data from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Purpose:Administration of the lymphocyte activation gene 3 (LAG-3) inhibitor relatlimab (RELA) and the PD-1 inhibitor nivolumab (NIVO) significantly prolonged progression-free survival (PFS) versus NIVO alone in patients with advanced mela…
View article: Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.